儿童青少年复发难治性侵袭性B细胞非霍奇金淋巴瘤的治疗
侵袭性B细胞非霍奇金淋巴瘤约占儿童青少年NHL的60%,初治五年无事件生存率约90%,但复发难治者治愈率低于30%且无标准治疗。含利妥昔单抗的挽救方案可使60-70%病例获得完全或部分缓解,但未移植者长期生存低于10%。自体或异基因造血干细胞移植是应答患者的最佳选择,生存率约50%,两者优劣尚不明确。
要点
- 复发难治儿童侵袭性B-NHL治愈率低于30%,无标准治疗。
- 含利妥昔单抗挽救方案完全/部分缓解率60-70%,未移植者长期生存低于10%。
- 自体或异基因造血干细胞移植是应答患者最佳选择,生存率约50%。
核心结论
- 复发难治儿童青少年侵袭性B-NHL预后差,治愈率低于30%,无标准治疗。
- 自体或异基因造血干细胞移植是应答患者的最佳选择,生存率约50%,但两者优劣不明确。
研究设计与样本
- 本文为综述,总结儿童青少年复发难治侵袭性B-NHL的治疗现状与在研新疗法。
主要发现
- 侵袭性B-NHL约占儿童青少年NHL的60%。
- 初治短程强化多药化疗的五年无事件生存率约90%。
- 含利妥昔单抗挽救方案可使60-70%病例获得完全或部分缓解。
- 未移植患者长期生存低于10%;移植应答患者生存率约50%。
临床怎么用
- 对复发难治儿童侵袭性B-NHL,应争取含利妥昔单抗挽救方案缓解后行自体或异基因造血干细胞移植。
局限性
- 自体与异基因造血干细胞移植的获益优劣尚不明确。
- 多数新型疗法在成人中试验,儿童青少年数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aggressive B-cell non-Hodgkin lymphoma (B-NHL) accounts for ≈60% of NHL in children/adolescents. In newly diagnosed Burkitt lymphoma and diffuse large B-cell lymphoma, short intensive multiagent chemotherapy is associated with a five-year event-free survival of around 90%. Very few children/adolescents with aggressive B-NHL show a relapsed/refractory (r/r) disease. The outcome is poor, with cure rates <30%, and there is no standard of care. Rituximab-containing salvage regimens may provide a complete/partial response in 60-70% of cases. However, long-term survival is <10% for non-transplanted patients. Autologous or allogeneic haematopoietic stem cell transplant is, nowadays, the best option for responding patients, with survival rates around 50%. The benefit of autologous versus allogeneic HSCT is not clear. Numerous novel therapies for r/r B-NHL are currently being tested in adults, including next-generation monoclonal antibodies, novel cellular therapy strategies and therapies directed against new targets. Some are under investigation also in children/adolescents, with promising preliminary results.
引用
- Moleti ML, Testi AM, Foà R, et al. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2020. PMID: 32141616. doi:10.1111/bjh.16461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。